pharmaphorum

MARCH 23, 2022

Vyvgart (efgartigimod alfa) became the first drug in the FcRn class to be approved by the FDA last December, and despite a $225,000 annual price tag is predicted to make relatively modest sales in its IV version, which will compete with other IV gMG drugs like AstraZeneca/Alexion’s C5 inhibitor Soliris (eculizumab). in the IV arm.

Antibody 52

Antibody Sales FDA Approval Trials 52

XTalks

JUNE 28, 2023

It is injected into a patient’s muscle tissue. million price tag of Elevidys, a one-time gene therapy. It has taken Sarepta six years to develop Elevidys with several roadblocks in its journey, including two clinical holds due to safety concerns. In a media call, Sarepta CEO Douglas Ingram revealed the $3.2

Gene Therapy 98

Gene Therapy Gene Protein FDA Approval 98

pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Joanna Carlish, managing director, financial services, Tag Americas. Virtual connections.

Regulation 91

Regulation Marketing Sales Branding 91

pharmaphorum

MAY 17, 2021

C5 inhibitor Soliris – which has a list price in the US of more than $500,000 per year – has been a standard therapy for the rare disorder since 2007, and was joined on the market by longer-acting follow-up Ultomiris in 2018 which launched with a price tag of around $450,000 per year. billion and $1.1

Drugs 52

Drugs FDA Approval Marketing Clinical Trials 52

Pharmaceutical Technology

APRIL 5, 2023

But access to these treatments continues to remain limited due to high price tags and variable availability across regions. With blood cancers, you inject the product, and the cells are there, and the target is there. We also have the challenge of delivery.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

pharmaphorum

JUNE 2, 2021

The orally-administered drug is the third approved treatment for SMA after Biogen’s injectable Spinraza (nusinersen) and Novartis’ one-shot gene therapy Zolgensma (onasemnogene abeparvovec), which was administered to the first NHS patient this week. — Spinal Muscular Atrophy UK (@SMA_UK_) June 2, 2021.

Gene Therapy 52

Gene Therapy Gene Drugs Medicine 52

XTalks

OCTOBER 12, 2022

For ASL MR perfusion, water molecules in arterial blood from a feeder artery are magnetically tagged and tracked until they reach the region of interest. Then, the signal difference in the region of interest between the tagged images and control images can be computed to obtain cerebral blood flow (CBF) values ( Figure 3 ).

Clinical Trials 93

Clinical Trials Clinical Trials Trials Drugs 93

pharmaphorum

AUGUST 26, 2022

BioMarin will no doubt have an eye on the earlier experience of bluebird bio, which secured EU approval for rare disease gene therapy Zynteglo (betibeglogene autotemcel) in 2019 for beta thalassaemia with a price tag of around €1.6 million spread over five years.

Gene Therapy 111

Gene Therapy Gene Antibody Marketing 111

pharmaphorum

DECEMBER 2, 2020

In 2015 the company also paid $17 billion to acquire Hospira , a firm specialising in injectable drugs and biosimilars, at a time when copycat biologics were starting to make real waves in the market. For all the latest Pfizer news follow pharmaphorum’s Pfizer tag. The post A history of Pfizer appeared first on.

Sales 128

Sales Production Drugs Marketing 128

XTalks

AUGUST 17, 2020

Cue Biopharma is a Cambridge, Massachusetts-based clinical-stage biotechnology company that is focused on developing injectable immune biologics using its proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform. Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

NOVEMBER 24, 2022

That can now be replaced with one injection of Hemgenix, which will enable patients to produce it continuously on their own in the liver. UniQure will manufacture Hemgenix at its Lexington, Massachusetts site. Conventional treatment for hemophilia B involves prophylactic infusions of factor IX replacement therapy.

Gene Therapy 52

Gene Therapy Gene FDA Approval Genetics 52

Rethinking Clinical Trials

AUGUST 4, 2022

It is a single injection of peginterferon lambda verses placebo, patients were randomized within 7 days of symptom onset and positive SARS-CoV-2 test. The arm evaluating Peginterferon Lambda is a multicenter, investigator sponsored, randomized placebo-controlled Phase 3 study in Brazil with 12 sites and Canada (5 sites).

Trials 130

Trials Vaccination Vaccine Clinical Trials 130

XTalks

MARCH 22, 2023

While not a record-breaking deal at $17 billion, the buyout strengthened Pfizer’s injectables business unit with the company reporting an 11 percent increase in revenue the following year. In addition, nearly half of all new drugs launched between 2020 and 2021 came with a price tag of $150,000 per year, or more.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

XTalks

FEBRUARY 11, 2021

Bacteriophages inject their DNA into cells but not protein, which is mainly a constituent of their outer envelope, or capsid. Through the radioactive labels, they were able to track which of the two, DNA or protein, was injected into the bacteria.

Genetics 119

Genetics DNA Genome Genomics 119

The Pharma Data

MAY 4, 2021

The study included an active control arm where patients were treated with dupilumab, a biologic treatment administered by subcutaneous injection. The study evaluated the safety and efficacy of two doses of abrocitinib, 100 mg and 200 mg, versus placebo in adults with moderate to severe atopic dermatitis who were on background topical therapy.

Vaccination 40

Vaccination Vaccine Production Sales 40